January 2014 | OncologyLive

Hopes Revived for Targeting the "Undruggable" RAS Family

February 11, 2014

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.

Six Targeted Agents for CLL Command Spotlight at ASH

February 10, 2014

A crop of targeted agents have demonstrated promising results in fighting chronic lymphocytic leukemia (CLL), suggesting that a range of emerging therapies and drug combinations may be more effective and better tolerated than standard chemotherapy

Clinical Trial Changes Needed to Improve Outcomes in Stage III NSCLC

February 04, 2014

Treatment of stage III non-small cell lung cancer (NSCLC) with chemotherapy, radiation, and surgery has hit a plateau, and the key to improved outcomes will hinge on the testing of targeted therapies in clinical trials with more novel designs and better patient selection, according to a leading researcher.

Pancreatic Cancer Starkly Illustrates Challenges of Developing Targeted Therapies

February 04, 2014

A recent study determined that it would take 6.7 years on average to enroll enough patients with pancreatic cancer for the trials that opened in 2011-a tall order considering that the 5-year relative survival rate for those diagnosed with pancreatic ductal adenocarcinoma is only 6%.

Sequencing Puzzles in CRPC Therapies Remain Unsolved

January 23, 2014

So many new agents for the treatment of men with castration-resistant prostate cancer (CRPC) have been introduced in the past several years that optimal sequencing of therapies remains an unsettled question.

Progress Remains Uneven

January 07, 2014

There's no question that the advent of molecularly targeted strategies in anticancer therapy have revolutionized the understanding and practice of oncology, but it also is clear that those gains have not been uniformly realized throughout the range of malignancies.